X @Bloomberg

Financial Performance - Sarepta Therapeutics' shares experienced a significant increase following the report of revenue exceeding estimates [1] Industry Dynamics - The revenue beat is partially attributed to a milestone payment for its gene therapy Elevidys [1] - Elevidys is described as a controversial gene therapy [1]